TearLab Reports on Launch of a New 1,000 Patient Multi-Center DED Prevalence Study in the UK

In collaboration with the United Kingdom's National Health Service (NHS), four ophthalmologists are beginning a large 1,000 patient multi-center study to assess the overall prevalence of Dry Eye Disease ("DED").

Patients who suffer from a wide variety of eye complications presenting daily in NHS clinics will be the primary target group of this study. Tear osmolarity testing will be incorporated as a diagnostic measure to detect the presence of DED. The study will be conducted under ethical controls, adopted by the National Institute of Health Research in the UK and will allow UK ophthalmologists to view DED in their own patient base.

"This is a unique opportunity to truly assess the prevalence of DED in a large patient population utilizing objective data, now available to us through osmolarity testing," commented Miss Francesca Harman, THH, a highly experienced NHS Consultant Ophthalmologist from the London area who will be leading the study.

About TearLab Corporation

TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab® Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding the future potential of the TearLab Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.

CONTACT: Stephen Kilmer
         [phone]
         [e-mail]